Pre-Market Scan: 5 Reasons Why MAIA Biotechnology (NYSE: MAIA) Is Topping My Watchlist Right Now

*Sponsored Market Crux’s Exclusive Coverage For Monday January 13th, 2025… See Why MAIA Biotechnology (NYSE: MAIA) is Topping  Our Early Morning Watchlist… (MAIA) Comes Stacked With Several Potential Catalysts Like: Key Markets: Targeting NSCLC ($34B), CRC ($20B), HCC ($3B), and SCLC ($2B), MAIA addresses key areas in oncology. Technical Indicators: Late Friday night (MAIA) triggered 14 Bullish Signals on TradingView, including the Momentum Indicator, underscoring strong near-term potential. Analyst Targets: Noble Capital’s $14.00 target suggests 573% upside potential; Diamond Equity’s $11.25 target suggests 440% upside potential. January 13, 2025 Dear Reader, Here’s what separates the early bids from the rest: Friday’s biotech saw an approximate 81% move before the bell even rang, and those who were ready saw their edge.  Now, the spotlight turns to another emerging player, and it’s one you can’t ignore.  Say hello to MAIA Biotechnology (NYSE: MAIA), a little-known biotech that’s topping our watchlist this morning. If you’re serious about spotting the next potential breakout, MAIA Biotechnology (NYSE: MAIA) needs to be on your radar today. Starting today, Dr. Vlad Vitoc, CEO of MAIA Biotechnology (NYSE: MAIA), is set to present at Biotech Showcase™ 2025 in San Francisco, one of the industry’s most anticipated conferences.  During the presentation, Dr. Vitoc will unveil key updates on (MAIA)’s pivotal THIO-101 Phase 2 expansion trial, which focuses on advanced non-small cell lung cancer (NSCLC) patients receiving third-line (3L) therapy.  He will also provide insights into (MAIA)’s plans for upcoming trials targeting multiple cancer indications, underscoring the company’s focus on addressing unmet needs in the global oncology market. A few days ago, on January 8th, Noble Capital Markets’ Robert LeBoyer pinned a $14.00 target on this one—which suggests a potential 573% upside from Friday’s $2.08 open. But even before that, Diamond Equity Research set their target at $11.25, pointing to 440% upside potential. And here’s the clincher: (MAIA) wasn’t just sitting idle on Friday night. Around 7:48 PM EST, it fired off 14 Bullish Signals on TradingView, including the coveted Momentum Indicator on the 5-minute chart. But is this just the tip of the iceberg why MAIA Biotechnology (NYSE: MAIA) is at the top of our watchlist this morning? Keep reading to find out… There’s plenty I could say about this company, but let me start with one word: Cancer. It’s the dreaded diagnosis that no one wants, yet countless individuals confront every year.  But MAIA Biotechnology (NYSE: MAIA) is fearlessly stepping into the arena with a weapon unlike anything we’ve seen before: telomere-targeting immunotherapies.  If you haven’t heard of (MAIA) yet, consider this your wake-up call.  A Game-Changer in Cancer Treatment MAIA Biotechnology (NYSE: MAIA) lead asset, THIO (6-thio-dG), is the first and only telomere-targeting agent in clinical development.  THIO operates with a dual mechanism of action (MoA): directly targeting telomeres to disrupt cancer cell replication while simultaneously activating an immune response to destroy the cancer cells. The Phase 2 THIO-101 trial focuses on non-small cell lung cancer (NSCLC), a market worth a staggering $34B annually.  Results? Nothing short of groundbreaking.  THIO followed by immune checkpoint inhibitors (ICIs) like Regeneron’s Libtayo® has demonstrated 60% complete response rates in preclinical models.  Patients achieved sustained remission after just two cycles of therapy, with no cancer recurrence—even after rechallenge with 5x the initial cancer cell load.  This isn’t just a treatment—it’s a potential revolution. Market Potential: Unmet Needs, Unrivaled Potential Cancer treatments are a high-stakes game, and (MAIA) is targeting the jackpot. NSCLC is the largest cancer market globally, and THIO is positioned to address patients who have become resistant to current checkpoint inhibitors—an enormous unmet need.  The U.S. FDA has already recognized THIO’s promise, granting Orphan Designations for small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), and glioblastoma (brain cancer). Let’s talk numbers: NSCLC: $34B annual sales. Checkpoint Inhibitors: $46B global market in 2023, with Keytruda alone generating $9B in NSCLC sales. HCC and SCLC: Combined annual sales of $5B with massive growth potential. MAIA Biotechnology (NYSE: MAIA) owns worldwide rights to THIO, securing the company’s stake in every dollar these markets generate. THIO-101: A Masterclass in Efficacy The THIO-101 trial has set a new standard for cancer therapies. Patients treated with THIO + Libtayo® showed a disease control rate (DCR) of 85%, far surpassing the 25–35% DCR achieved by traditional chemotherapy.  Even in third-line (3L) settings—where options are typically grim—THIO delivered unprecedented outcomes: Median progression-free survival (PFS): 2.5 months (compared to 1.5 months with chemotherapy). Median overall survival (OS): 5.8 months (nearly double the historical benchmark). Objective response rate (ORR): 38%, a dramatic leap from the 6–10% seen with chemotherapy. These results underscore one thing: THIO is not just effective; it’s transformative. Building the Pipeline: (MAIA)’s Vision for the Future (MAIA) isn’t stopping at NSCLC. With a robust pipeline of trials planned for colorectal cancer (CRC), SCLC, HCC, and other solid tumors, the company is poised to address multiple high-value cancer indications.  Interestingly, preclinical models in CRC demonstrated a 100% complete response rate with long-term immune memory formation. The strategy?  Expand THIO’s applications while leveraging collaborations with big pharma players like Regeneron.  MAIA Biotechnology (NYSE: MAIA) Expands Collaboration with Regeneron, a +$76B Industry Leader Less than six weeks ago, on December 3, 2024, MAIA Biotechnology (NYSE: MAIA) announced the expansion of its clinical supply agreement with Regeneron, a +$76B industry leader, for the ongoing Phase 2 THIO-101 trial.  This partnership focuses on evaluating MAIA's lead asset, THIO, in combination with Regeneron’s Libtayo® (cemiplimab), an immune checkpoint inhibitor.  The trial targets advanced non-small cell lung cancer (NSCLC) patients resistant to prior checkpoint inhibitor therapies and chemotherapy. Initially signed in 2021, the agreement was designed to supply Libtayo® during the dose selection and safety evaluation stages.  The expanded agreement now supports a broader patient population to assess THIO’s efficacy at the optimal dose. Regeneron provides Libtayo® for all trial patients, while MAIA sponsors the study and retains exclusive global rights to develop and commercialize THIO. This collaboration highlights Regeneron's confidence in THIO’s potential to enhance checkpoint inhibitor outcomes.  With THIO demonstrating promising disease control, progression-free survival, and overall response rates, MAIA Biotechnology (NYSE: MAIA) is advancing its regulatory pathway and exploring the potential for accelerated U.S. approval based on trial results.  Beyond the expansion of THIO-101, the company is systematically building a robust pipeline of Phase 2/3 trials, including THIO-102 (targeting CRC, HCC, and SCLC) and THIO-103 (first-line NSCLC).  Together, these initiatives position MAIA as a biotech powerhouse with a portfolio designed for long-term growth. Intellectual Property: Locking in the Advantage (MAIA)’s intellectual property portfolio is as robust as its science. The company holds five issued patents and 29 pending applications covering telomere-targeting compounds and THIO’s immunogenic treatment strategy.  With exclusivity agreements extending to 2041, MAIA is ensuring its technology remains unrivaled for decades. Leadership: Experience That Delivers MAIA Biotechnology (NYSE: MAIA)’s team brings over 70 years of combined experience in oncology and biotech.  CEO Dr. Vlad Vitoc has led the launch of 12 oncology compounds across 20 tumor types, while CSO Dr. Sergei Gryaznov—the co-inventor of THIO—is a global authority on telomeres and cancer. This isn’t their first rodeo, and it shows. The Bottom Line MAIA Biotechnology (NYSE: MAIA) is not just another biotech company. It’s a disruptor, a trailblazer, and quite possibly the future of cancer treatment.  With a pipeline brimming with potential, collaborations with leading industry players, and a market valued in the high ranges, (MAIA) stands out as a company to keep on your radar. In the fight against cancer, (MAIA) is bringing the big guns.  And if their data is anything to go by, this is one company to keep an eye on. 5 Reasons Why MAIA Biotechnology (NYSE: MAIA) is Taking the Top Spot On Our Watchlist This Morning… 1. Momentum and Spotlight: MAIA recently triggered 14 Bullish Signals on TradingView and is stealing the show at Biotech Showcase™ 2025, where CEO Dr. Vlad Vitoc is revealing pivotal updates on THIO-101 and future plans. 2. Analyst Coverage: With Noble Capital Markets projecting a $14.00 target (573% upside) and Diamond Equity Research estimating $11.25 (440% upside), MAIA’s growth potential is catching serious attention. 3. Commanding Key Markets MAIA targets some of the largest and most critical markets in oncology, including non-small cell lung cancer ($34B), colorectal cancer ($20B), liver cancer ($3B), and small cell lung cancer ($2B). 4. Game-Changing Science and Results: THIO, the first telomere-targeting agent in development, combines a dual mechanism of action with standout clinical results: an 85% disease control rate and a 38% objective response rate, far surpassing conventional therapies. 5. Exclusive Innovation: With five issued patents and 29 pending applications locking in exclusivity through 2041, MAIA’s intellectual property portfolio secures its position as a leader in telomere-targeting therapies. Keeping An Eye On MAIA Biotechnology (NYSE: MAIA) This Week… MAIA Biotechnology (NYSE: MAIA) is proving itself to be more than just another biotech—it’s a trailblazer in the fight against cancer. With 14 Bullish Signals recently triggered on TradingView and CEO Dr. Vlad Vitoc captivating audiences at Biotech Showcase™ 2025, the momentum is undeniable. Analysts are taking notice, with targets from Noble Capital Markets and Diamond Equity Research pointing to an upside potential of 573% and 440%, respectively.  And it’s not just projections driving excitement; (MAIA) is tackling some of oncology’s biggest markets, including non-small cell lung cancer ($34B) and colorectal cancer ($20B). At the heart of this is THIO, a groundbreaking therapy delivering results that outshine traditional treatments with an 85% disease control rate and a 38% objective response rate.  Combined with an ironclad intellectual property portfolio securing exclusivity through 2041, (MAIA) is not just leading—it’s redefining the telomere-targeting space. If the data is any indication, MAIA Biotechnology (NYSE: MAIA) isn’t just making progress—it’s making history. Consider pulling up (MAIA) before the opening bell rings this morning. It’s at the top of our screens right now. We’re excited about (MAIA) today, especially right now, while it’s still early. Keep a lookout for my next update. Give me a few minutes and keep a lookout for my next update. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired by TD Media LLC for a period beginning on 01/12/2025 and ending on 01/13/2025 to publicly disseminate information about (MAIA:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”) to disseminate information about (MAIA:US) via digital communications. These Funds were part of the funds that TD Media LLC received from a third party who did not receive the funds from the issuer and does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC or their members own shares of (MAIA:US). Please see important disclosure information here: https://marketcrux.com/disclosure/maia/

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice